Mechanism

Evidence tier: 4 — Mechanism characterized in rodent adipocyte assays; downstream clinical effect in humans was negative in the largest registration-quality trial.

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to residues 176-191 of human growth hormone (hGH) with an added tyrosine at the N-terminus. The molecule was developed at Monash University in the 1990s and licensed to Metabolic Pharmaceuticals as a candidate lipolytic agent — the hypothesis was that this fragment captured hGH's lipolytic mechanism without the broader endocrine and growth-promoting effects of the full hormone.

The proposed mechanism is selective lipolysis without IGF-1 stimulation. In rodent adipocyte assays, AOD-9604 stimulated fat breakdown comparable to full-length hGH while not measurably affecting IGF-1 levels, insulin sensitivity, or growth-promoting effects. The mechanistic hypothesis was that the C-terminal hGH fragment retains hGH's lipolytic effects (via β3-adrenergic receptor sensitization and other adipocyte-level signaling) while lacking the dimerized-receptor activation required for growth-hormone receptor signaling that drives IGF-1 and growth effects.

Whether this clean mechanistic distinction translates to humans was the central question of the clinical-development program. The answer in the largest Phase 2b trial was that it did not — AOD-9604 failed to produce statistically significant weight-loss over placebo in a registration-quality trial. The molecule does not appear to engage human fat metabolism the way the rodent-adipocyte work predicted, for reasons that have not been fully characterized.

The mechanism is interesting in principle but the clinical translation failed. The molecule's continued use in research-supplier and compounded-peptide channels is essentially a continuation of the mechanistic hypothesis despite the negative clinical evidence.

Typical protocols

Evidence tier: 5 — No FDA-approved protocol; community use circulates Phase 2-derived doses.

AOD-9604 is not FDA-approved for any indication. The Phase 2 and 2b trial doses were oral (1 mg, 5 mg, 10 mg, 30 mg per day in various dose-finding arms) over 12-24 week treatment courses. Oral bioavailability of AOD-9604 is modest, which is one reason community protocols typically use the subcutaneous route rather than oral.

Community-circulated protocols typically describe 300-500 mcg subcutaneously per day, administered in the morning, often combined with other peptides (CJC-1295/Ipamorelin or BPC-157) in stacked protocols marketed for weight loss or joint support. These protocols are not RCT-validated for any indication. Some community protocols frame AOD-9604 as an adjunct for joint cartilage support; the cartilage-protection claim is hypothesis-generated rather than RCT-supported.

The honest framing on protocols: the Phase 2b failure means there is no validated dosing schema for any human indication. Compounded AOD-9604 is supplied by some 503A pharmacies on a research-use framing; the molecule's place in the broader compounded-peptide marketplace exists despite the failed clinical-development program rather than because of it.

Evidence by indication

Evidence tier: 1 for the negative weight-loss result; 3-4 for hypothesized cartilage effects.

Weight loss / lipolysis (Phase 2b): The 24-week Phase 2b trial in 536 obese subjects was the registration-quality study designed to establish AOD-9604's clinical efficacy for weight loss. The trial failed to show a statistically significant weight-loss difference between AOD-9604 and placebo across the full study population. Metabolic Pharmaceuticals terminated the weight-loss development program in 2007 after these results, and the molecule did not advance to Phase 3. An earlier 12-week Phase 2a trial in 300 subjects had shown a modest signal (2.6 kg vs 0.8 kg placebo) that did not replicate at scale.

Cartilage and joint support: A separate line of research has explored AOD-9604 as a joint-support adjunct, with claims about cartilage regeneration and osteoarthritis-symptom improvement. This work is largely preclinical or open-label and is not supported by RCT-grade evidence for any specific joint indication. The cartilage-effect hypothesis is mechanistic speculation extrapolated from broader hGH-pathway joint biology.

Nutraceutical/functional-food applications: AOD-9604 has been explored as a nutraceutical ingredient with claims about metabolic health improvement; the underlying evidence is consistent with the failed weight-loss program — modest signals in small studies, no replication at scale.

Athletic and body-composition use: Off-label community use for body-composition optimization is widespread despite the negative Phase 2b weight-loss data. There is no RCT-grade evidence supporting these use cases.

The defining clinical-evidence reality of AOD-9604 is the failed Phase 2b weight-loss trial. Continued use in compounded and research-supplier channels operates against this evidence rather than building on positive data.

Safety profile

Evidence tier: 2 — Phase 2 RCT AE data; long-term human safety not characterized.

The Phase 2 and 2b AOD-9604 trials documented a favorable short-term safety profile — the molecule did not show significant adverse events at studied doses. There was no signal for the cardiometabolic, glycemic, or endocrine concerns that would have raised regulatory red flags. The Phase 2b trial's failure was an efficacy failure, not a safety failure.

Documented adverse events were limited to mild and uncommon — nausea, headache, injection-site reactions for the subcutaneous route. No clinically significant changes in IGF-1, insulin sensitivity, or growth-hormone-axis function were observed in the Phase 2 dataset.

Theoretical concerns and unknowns include long-term safety with chronic dosing (not characterized in any trial), immunogenicity of the synthetic 16-aa peptide with repeated administration, drug-drug interactions, and research-supplier purity/contamination concerns. Patients with active malignancy should not consider AOD-9604 given the unresolved questions about hGH-pathway interactions and malignancy risk (a concern that applies more strongly to full-length hGH than to this fragment but cannot be fully ruled out).

Contraindications by analogy with the broader GH-pathway peptide class: active malignancy, pregnancy/lactation, severe diabetic retinopathy. Discuss with a clinician before considering AOD-9604 for any indication.

Where it fits relative to alternatives

Evidence tier: 5 — Editorial positioning.

In the weight-loss peptide landscape:

Semaglutide (Wegovy, FDA-approved): ~15% weight loss, RCT-grade evidence, established safety
Tirzepatide (Zepbound, FDA-approved): ~22% weight loss, RCT-grade, current first-line injectable
Retatrutide (Phase 3): ~24-29% weight loss
Orforglipron (Phase 3, oral): ~12-15% weight loss
CagriSema (Phase 3 complete): ~22.7% weight loss
Tesofensine: Failed Phase 3, used compounded outside US
AOD-9604: Failed Phase 2b, no validated indication

AOD-9604's position in the obesity hierarchy is essentially nonexistent — there is no clinical evidence supporting its use for weight loss, and the validated GLP-1-class options provide RCT-grade weight-loss effects that AOD-9604 has never demonstrated. The continued presence of AOD-9604 in compounded and research-supplier channels reflects market demand and the molecule's history rather than its efficacy.

For patients seeking weight-loss pharmacotherapy, the appropriate path is discussion with a clinician about FDA-approved GLP-1-class options. For patients seeking joint or cartilage support, BPC-157 and TB-500 have more (though still limited) evidence for connective-tissue indications than AOD-9604.

Regulatory status + access

Evidence tier: 5 — Regulatory-process content.

AOD-9604 is not FDA-approved for any indication. The molecule failed Phase 2b and did not advance to Phase 3. It is on the FDA bulks list for 503A compounding in some interpretations, though the compounding-eligibility status has been subject to enforcement-priority changes — patients should verify current status with a compounding pharmacy. The molecule is available through some 503A compounding pharmacies on a prescription basis and through research-supplier channels. WADA: AOD-9604 has been on the WADA prohibited list as a growth-hormone-related substance — athletes subject to WADA testing should not use it. Patients considering AOD-9604 for weight loss should discuss the failed Phase 2b data with a clinician and consider the FDA-approved GLP-1-class alternatives as a categorically better-evidenced path.

References

Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PMID 33567185 — cited as RCT-grade weight-loss alternative.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. 2022. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. PMID 35658024 — cited as RCT-grade weight-loss alternative; SURMOUNT-1.

Limitations

This page does not constitute medical advice. AOD-9604 sits in a regulatorily ambiguous category — the molecule completed Phase 2 with a negative efficacy result for weight loss and did not advance to Phase 3, but compounded and research-supplier supply continues in the broader peptide marketplace. Patients seeking weight-loss pharmacotherapy should discuss FDA-approved GLP-1-class options with a clinician rather than pursuing AOD-9604, which has no RCT-grade evidence of weight-loss efficacy in humans. The cartilage and joint-support hypotheses are unvalidated. Patients with active malignancy, pregnancy, or significant cardiometabolic risk factors should not consider this molecule. We would update our framing if a new well-powered RCT of AOD-9604 produced positive efficacy data for any indication, or if FDA action altered the compounding-eligibility status materially.

AOD-9604